Synthetic lethality-based therapeutics: Perspectives for applications in colorectal cancer

Current Cancer Drug Targets

Volumn 12, Issue 4, 2012, Pages 329-338

  Soncini, D ^a   Caffa, I ^a   Patrone, F ^a   Ballestrero, A ^a   Nencioni, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Colorectal cancer; Drug screenings; Molecularly targeted agents; MYC; RAS; Synthetic lethality

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE 3BETA; MRE11 PROTEIN; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH2; PROTEIN P53; SMALL INTERFERING RNA; TEMOZOLOMIDE; TEMSIROLIMUS; VELIPARIB; WNT PROTEIN;

ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DNA REPAIR; DRUG EFFICACY; DRUG TOLERABILITY; GENE MUTATION; GENE PRODUCT; GENE SILENCING; GENOTOXICITY; HUMAN; LETHALITY; MAMMAL CELL; MISMATCH REPAIR; ONCOGENE; OVERALL SURVIVAL; QUALITY OF LIFE; SIGNAL TRANSDUCTION;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; HUMANS; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84860307676     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800190938     Document Type: Article

References (78)

1. Cunningham, D.; Atkin, W.; Lenz, H. J.; Lynch, H. T.; Minsky, B.; Nordlinger, B.; Starling, N. Colorectal cancer. Lancet 2010, 375 (9719), 1030-1047.
2. Cejas, P.; Lopez-Gomez, M.; Aguayo, C.; Madero, R.; de Castro Carpeno, J.; Belda-Iniesta, C.; Barriuso, J.; Moreno Garcia, V.; Larrauri, J.; Lopez, R.; Casado, E.; Gonzalez-Baron, M.; Feliu, J. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PloS one 2009, 4 (12), e8199.
3. Delaunoit, T.; Alberts, S. R.; Sargent, D. J.; Green, E.; Goldberg, R. M.; Krook, J.; Fuchs, C.; Ramanathan, R. K.; Williamson, S. K.; Morton, R. F.; Findlay, B. P. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann. Oncol. 2005, 16 (3), 425-429.
4. Giacchetti, S.; Itzhaki, M.; Gruia, G.; Adam, R.; Zidani, R.; Kunstlinger, F.; Brienza, S.; Alafaci, E.; Bertheault-Cvitkovic, F.; Jasmin, C.; Reynes, M.; Bismuth, H.; Misset, J. L.; Levi, F. Longterm survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol. 1999, 10 (6), 663-669.
5. Moehler, M.; Teufel, A.; Galle, P. R. New chemotherapeutic strategies in colorectal cancer. Recent Results Cancer Res. 2005, 165, 250-259.
6. Markman, B.; Javier Ramos, F.; Capdevila, J.; Tabernero, J. EGFR and KRAS in colorectal cancer. Adv. Clin. Chem. 2010, 51, 71-119.
7. Leong, S.; Messersmith, W. A.; Tan, A. C.; Eckhardt, S. G. Novel agents in the treatment of metastatic colorectal cancer. Cancer J. 2010, 16 (3), 273-282.
8. Bardelli, A.; Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Onco. 2010, 28 (7), 1254-1261.
9. Chen, J.; Huang, X. F.; Katsifis, A. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J. Cell Biochem. 2010, 111 (5), 1082-6.
10. Kaelin, W. G., Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5 (9), 689-698.
11. Markowitz, S. D.; Bertagnolli, M. M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361 (25), 2449-2460.
12. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui- Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361 (2), 123-134.
13. Ooi, S. L.; Pan, X.; Peyser, B. D.; Ye, P.; Meluh, P. B.; Yuan, D. S.; Irizarry, R. A.; Bader, J. S.; Spencer, F. A.; Boeke, J. D. Global synthetic-lethality analysis and yeast functional profiling. Trends Genet. 2006, 22 (1), 56-63.
14. Nijman, S. M. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS letters 2011, 585 (1), 1-6.
15. Kroll, E. S.; Hyland, K. M.; Hieter, P.; Li, J. J. Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 1996, 143 (1), 95-102.
16. Chan, D. A.; Giaccia, A. J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat. Rev. Drug Discov. 2011, 10 (5), 351-364.
17. Weinstein, I. B.; Joe, A. Oncogene addiction. Cancer Res. 2008, 68 (9), 3077-3080.
18. Sharma, S. V.; Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21 (24), 3214-3231.
19. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434 (7035), 913-917.
20. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434 (7035), 917-921.
21. El-Khamisy, S. F.; Masutani, M.; Suzuki, H.; Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003, 31 (19), 5526-5533.
22. Patel, A.; Kaufmann, S. H. Development of PARP inhibitors: an unfinished story. Oncology 2010, 24 (1), 66-68.
23. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411 (6835), 366-374.
24. Edwards, S. L.; Brough, R.; Lord, C. J.; Natrajan, R.; Vatcheva, R.; Levine, D. A.; Boyd, J.; Reis-Filho, J. S.; Ashworth, A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451 (7182), 1111-1115.
25. Sakai, W.; Swisher, E. M.; Karlan, B. Y.; Agarwal, M. K.; Higgins, J.; Friedman, C.; Villegas, E.; Jacquemont, C.; Farrugia, D. J.; Couch, F. J.; Urban, N.; Taniguchi, T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451 (7182), 1116-1120.
26. Anders, C. K.; Winer, E. P.; Ford, J. M.; Dent, R.; Silver, D. P.; Sledge, G. W.; Carey, L. A. Poly(ADP-Ribose) polymerase inhibition: targeted therapy for triple-negative breast cancer. Clin. Cancer Res. 2010, 16 (19), 4702-4710.
27. Chan, N.; Pires, I. M.; Bencokova, Z.; Coackley, C.; Luoto, K. R.; Bhogal, N.; Lakshman, M.; Gottipati, P.; Oliver, F. J.; Helleday, T.; Hammond, E. M.; Bristow, R. G. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010, 70 (20), 8045-8054.
28. Dedes, K. J.; Wilkerson, P. M.; Wetterskog, D.; Weigelt, B.; Ashworth, A.; Reis-Filho, J. S. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011, 10 (8), 1192-1199.
29. Vilar, E.; Bartnik, C. M.; Stenzel, S. L.; Raskin, L.; Ahn, J.; Moreno, V.; Mukherjee, B.; Iniesta, M. D.; Morgan, M. A.; Rennert, G.; Gruber, S. B. MRE11 deficiency increases sensitivity to Poly(ADP-ribose) Polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011, 71 (7), 2632-2642.
30. Mendes-Pereira, A. M.; Martin, S. A.; Brough, R.; McCarthy, A.; Taylor, J. R.; Kim, J. S.; Waldman, T.; Lord, C. J.; Ashworth, A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1 (6-7), 315-322.
31. Dedes, K. J.; Wetterskog, D.; Mendes-Pereira, A. M.; Natrajan, R.; Lambros, M. B.; Geyer, F. C.; Vatcheva, R.; Savage, K.; Mackay, A.; Lord, C. J.; Ashworth, A.; Reis-Filho, J. S. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2010, 2 (53), 53-75.
32. Shen, W. H.; Balajee, A. S.; Wang, J.; Wu, H.; Eng, C.; Pandolfi, P. P.; Yin, Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128 (1), 157-170.
33. Wedge, S. R.; Porteous, J. K.; Newlands, E. S. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer 1996, 74 (7), 1030-1036.
34. Curtin, N. J.; Wang, L. Z.; Yiakouvaki, A.; Kyle, S.; Arris, C. A.; Canan-Koch, S.; Webber, S. E.; Durkacz, B. W.; Calvert, H. A.; Hostomsky, Z.; Newell, D. R. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 2004, 10 (3), 881-889.
35. Martin, S. A.; McCarthy, A.; Barber, L. J.; Burgess, D. J.; Parry, S.; Lord, C. J.; Ashworth, A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 2009, 1 (6/7), 323-337.
36. Malumbres, M.; Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 2003, 3 (6), 459-465.
37. Giehl, K. Oncogenic Ras in tumour progression and metastasis. Biol. Chem. 2005, 386 (3), 193-205.
38. Tabin, C. J.; Bradley, S. M.; Bargmann, C. I.; Weinberg, R. A.; Papageorge, A. G.; Scolnick, E. M.; Dhar, R.; Lowy, D. R.; Chang, E. H. Mechanism of activation of a human oncogene. Nature 1982, 300 (5888), 143-149.
39. Reddy, E. P.; Reynolds, R. K.; Santos, E.; Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982, 300 (5888), 149-52.
40. Kranenburg, O. The KRAS oncogene: past, present, and future. Biochim. Biophys. Acta 2005, 1756 (2), 818-812.
41. Wong, R.; Cunningham, D. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J. Clin. Oncol. 2008, 26 (35), 5668-5670.
42. Fearon, E. R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61 (5), 759-767.
43. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3 (1), 11-22.
44. Ellis, C. A.; Clark, G. The importance of being K-Ras. Cell Signal. 2000, 12 (7), 425-434.
45. Morgillo, F.; Lee, H. Y. Lonafarnib in cancer therapy. Expert Opin. Investig. Drugs 2006, 15 (6), 709-719.
46. Baldus, S. E.; Schaefer, K. L.; Engers, R.; Hartleb, D.; Stoecklein, N. H.; Gabbert, H. E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 2010, 16 (3), 790-799.
47. Barbie, D. A.; Tamayo, P.; Boehm, J. S.; Kim, S. Y.; Moody, S. E.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Meylan, E.; Scholl, C.; Frohling, S.; Chan, E. M.; Sos, M. L.; Michel, K.; Mermel, C.; Silver, S. J.; Weir, B. A.; Reiling, J. H.; Sheng, Q.; Gupta, P. B.; Wadlow, R. C.; Le, H.; Hoersch, S.; Wittner, B. S.; Ramaswamy, S.; Livingston, D. M.; Sabatini, D. M.; Meyerson, M.; Thomas, R. K.; Lander, E. S.; Mesirov, J. P.; Root, D. E.; Gilliland, D. G.; Jacks, T.; Hahn, W. C. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462 (7269), 108-112.
48. Scholl, C.; Frohling, S.; Dunn, I. F.; Schinzel, A. C.; Barbie, D. A.; Kim, S. Y.; Silver, S. J.; Tamayo, P.; Wadlow, R. C.; Ramaswamy, S.; Dohner, K.; Bullinger, L.; Sandy, P.; Boehm, J. S.; Root, D. E.; Jacks, T.; Hahn, W. C.; Gilliland, D. G. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137 (5), 821-834.
49. Luo, J.; Emanuele, M. J.; Li, D.; Creighton, C. J.; Schlabach, M. R.; Westbrook, T. F.; Wong, K. K.; Elledge, S. J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137 (5), 835-848.
50. Puyol, M.; Martin, A.; Dubus, P.; Mulero, F.; Pizcueta, P.; Khan, G.; Guerra, C.; Santamaria, D.; Barbacid, M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18 (1), 63-73.
51. Yun, J.; Rago, C.; Cheong, I.; Pagliarini, R.; Angenendt, P.; Rajagopalan, H.; Schmidt, K.; Willson, J. K.; Markowitz, S.; Zhou, S.; Diaz, L. A., Jr.; Velculescu, V. E.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B.; Papadopoulos, N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325 (5947), 1555-1559.
52. Dolma, S.; Lessnick, S. L.; Hahn, W. C.; Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003, 3 (3), 285-296.
53. Yang, W. S.; Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 2008, 15 (3), 234-245.
54. Yagoda, N.; von Rechenberg, M.; Zaganjor, E.; Bauer, A. J.; Yang, W. S.; Fridman, D. J.; Wolpaw, A. J.; Smukste, I.; Peltier, J. M.; Boniface, J. J.; Smith, R.; Lessnick, S. L.; Sahasrabudhe, S.; Stockwell, B. R. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007, 447 (7146), 864-868.
55. Efeyan, A.; Serrano, M. P53: guardian of the genome and policeman of the oncogenes. Cell cycle 2007, 6 (9), 1006-1010.
56. Liu, Y.; Kulesz-Martin, M. P53 protein at the hub of cellular DNA damage response pathways through sequence-specific and nonsequence- specific DNA binding. Carcinogenesis 2001, 22 (6), 851-860.
57. Takayama, T.; Miyanishi, K.; Hayashi, T.; Sato, Y.; Niitsu, Y. Colorectal cancer: genetics of development and metastasis. J. Gastroenterol. 2006, 41 (3), 185-192.
58. Wiman, K. G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010, 29 (30), 4245-4252.
59. Reinhardt, H. C.; Jiang, H.; Hemann, M. T.; Yaffe, M. B. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009, 8 (19), 3112-3119.
60. Jiang, H.; Reinhardt, H. C.; Bartkova, J.; Tommiska, J.; Blomqvist, C.; Nevanlinna, H.; Bartek, J.; Yaffe, M. B.; Hemann, M. T. The ombined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009, 23 (16), 1895-1909.
61. Albihn, A.; Johnsen, J. I.; Henriksson, M. A. MYC in oncogenesis and as a target for cancer therapies. Adv. Cancer Res. 2010, 107, 163-224.
62. Erisman, M. D.; Rothberg, P. G.; Diehl, R. E.; Morse, C. C.; Spandorfer, J. M.; Astrin, S. M. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol. Cell Biol. 1985, 5 (8), 1969-1976.
63. Sansom, O. J.; Meniel, V. S.; Muncan, V.; Phesse, T. J.; Wilkins, J. A.; Reed, K. R.; Vass, J. K.; Athineos, D.; Clevers, H.; Clarke, A. R. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446 (7136), 676-679.
64. Yang, D.; Liu, H.; Goga, A.; Kim, S.; Yuneva, M.; Bishop, J. M. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (31), 13836-13841.
65. Green, M. R.; Woolery, J. E.; Mahadevan, D. Update on aurora kinase targeted therapeutics in oncology. Expert Opin. Drug Discov. 2011, 6 (3), 291-307.
66. Ruchaud, S.; Carmena, M.; Earnshaw, W. C. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 2007, 8 (10), 798-812.
67. den Hollander, J.; Rimpi, S.; Doherty, J. R.; Rudelius, M.; Buck, A.; Hoellein, A.; Kremer, M.; Graf, N.; Scheerer, M.; Hall, M. A.; Goga, A.; von Bubnoff, N.; Duyster, J.; Peschel, C.; Cleveland, J. L.; Nilsson, J. A.; Keller, U. Aurora kinases A and B are upregulated by Myc and are essential for maintenance of the malignant state. Blood 2010, 116 (9), 1498-1505.
68. Kessler, J. D.; Kahle, K. T.; Sun, T.; Meerbrey, K. L.; Schlabach, M. R.; Schmitt, E. M.; Skinner, S. O.; Xu, Q.; Li, M. Z.; Hartman, Z. C.; Rao, M.; Yu, P.; Dominguez-Vidana, R.; Liang, A. C.; Solimini, N. L.; Bernardi, R. J.; Yu, B.; Hsu, T.; Golding, I.; Luo, J.; Osborne, C. K.; Creighton, C. J.; Hilsenbeck, S. G.; Schiff, R.; Shaw, C. A.; Elledge, S. J.; Westbrook, T. F. A SUMOylation dependent transcriptional subprogram is required for myc-driven tumorigenesis. Science 2011, [Epub ahead of print].
69. Zhang, X. Y.; Pfeiffer, H. K.; Mellert, H. S.; Stanek, T. J.; Sussman, R. T.; Kumari, A.; Yu, D.; Rigoutsos I.; Thomas-Tikhonenko, A.; Seidel, H. E.; Chodosh, L. A.; Packham, G.; Baserga, R.; McMahon, S. B. Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYC. Mol. Cell Biol. 2011 31(24), 5037-5045.
70. Huang, S. M.; Mishina, Y. M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G. A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; Hild, M.; Shi, X.; Wilson, C. J.; Mickanin, C.; Myer, V.; Fazal, A.; Tomlinson, R.; Serluca, F.; Shao, W.; Cheng, H.; Shultz, M.; Rau, C.; Schirle, M.; Schlegl, J.; Ghidelli, S.; Fawell, S.; Lu, C.; Curtis, D.; Kirschner, M. W.; Lengauer, C.; Finan, P. M.; Tallarico, J. A.; Bouwmeester, T.; Porter, J. A.; Bauer, A.; Cong, F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461 (7264), 614-620.
71. Naik, S.; Dothager, R. S.; Marasa, J.; Lewis, C. L.; Piwnica-Worms, D., Vascular Endothelial Growth Factor Receptor-1 is synthetic lethal to Aberrant {beta}-Catenin activation in colon cancer. Clin. Cancer Res. 2009, 15 (24), 7529-7537.
72. Dong, Y.; Li, A.; Wang, J.; Weber, J. D.; Michel, L. S. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010, 70 (13), 5465-5474.
73. Leary, R. J.; Lin, J. C.; Cummins, J.; Boca, S.; Wood, L. D.; Parsons, D. W.; Jones, S.; Sjoblom, T.; Park, B. H.; Parsons, R.; Willis, J.; Dawson, D.; Willson, J. K.; Nikolskaya, T.; Nikolsky, Y.; Kopelovich, L.; Papadopoulos, N.; Pennacchio, L. A.; Wang, T. L.; Markowitz, S. D.; Parmigiani, G.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E., Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (42), 16224-16229.
74. Wood, L. D.; Parsons, D. W.; Jones, S.; Lin, J.; Sjoblom, T.; Leary, R. J.; Shen, D.; Boca, S. M.; Barber, T.; Ptak, J.; Silliman, N.; Szabo, S.; Dezso, Z.; Ustyanksky, V.; Nikolskaya, T.; Nikolsky, Y.; Karchin, R.; Wilson, P. A.; Kaminker, J. S.; Zhang, Z.; Croshaw, R.; Willis, J.; Dawson, D.; Shipitsin, M.; Willson, J. K.; Sukumar, S.; Polyak, K.; Park, B. H.; Pethiyagoda, C. L.; Pant, P. V.; Ballinger, D. G.; Sparks, A. B.; Hartigan, J.; Smith, D. R.; Suh, E.; Papadopoulos, N.; Buckhaults, P.; Markowitz, S. D.; Parmigiani, G.; Kinzler, K. W.; Velculescu, V. E.; Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318 (5853), 1108-1113.
75. Neshat, M. S.; Mellinghoff, I. K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.; Gibbons, J. J.; Wu, H.; Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (18), 10314-10319.
76. Zhang, L.; Ren, X.; Alt, E.; Bai, X.; Huang, S.; Xu, Z.; Lynch, P. M.; Moyer, M. P.; Wen, X. F.; Wu, X. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 2010, 464 (7291), 1058-1061.
77. Jinek, M.; Doudna, J. A. A three-dimensional view of the molecular machinery of RNA interference. Nature 2009, 457 (7228), 405-412.
78. Hartwell, L. H.; Szankasi, P.; Roberts, C. J.; Murray, A. W.; Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278 (5340), 1064-1068.